Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Rx Abuse Monitoring Bill Awaits House, Senate Floor Votes

This article was originally published in The Pink Sheet Daily

Executive Summary

The House and Senate could vote on the "National All Schedules Prescription Electronic Reporting Act" following an agreement by committees to send an identical version to their respective floors. Under HR 1132, states would receive grants to create or augment monitoring systems to track prescriptions of Schedule II-IV drugs across state lines.

You may also be interested in...



Dispensation Of Schedule II-IV Drugs Must Be Reported Within A Week Under New Law

The National All Schedules Prescription Electronic Reporting Act authorizes $60 mil. over five years for states to create or augment Rx monitoring programs.

Dispensation Of Schedule II-IV Drugs Must Be Reported Within A Week Under New Law

The National All Schedules Prescription Electronic Reporting Act authorizes $60 mil. over five years for states to create or augment Rx monitoring programs.

Rx Controlled Substances Bills Head To President’s Desk

The bills would ease restrictions on exporting controlled substances and limitations on medical practices that treat drug-addicted patients.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS062616

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel